Literature DB >> 14965302

Modulation of the immune response by the cholera-like enterotoxins.

Andrea Plant1, Neil A Williams.   

Abstract

Cholera toxins and heat labile enterotoxin from E. coli differ from most soluble proteins in eliciting systemic immunity both against themselves and unrelated admixed antigens, rather than tolerance following administration to a mucosal surface. Several reports have also demonstrated preferential induction of Th2-type responses when these molecules are used as adjuvants. Conversely, these proteins and their non-toxic derivatives, including the B sub-units are also able prevent and alleviate autoimmune diseases in naïve and systemically immune hosts demonstrating wide-ranging effects on the immune system. The recent observation that amelioration of autoimmune disease is associated with the generation of regulatory T cells which inhibit pathogenic Th1 responses may also help to consolidate these two apparently contradictory outcomes of exposure to the cholera-like enterotoxins. Furthermore, the observation that EtxB is able to alleviate autoimmune disease in the absence of conjugation to autoantigen highlights its potential for use in the clinical setting where the target antigen is often unknown. Direct effects on T cells, B cells and APC have been demonstrated in vitro which have provided insights into how these molecules may elicit these diverse effects. Further investigation is required for elucidation of the mechanisms of action of adjuvanticity and tolerance induction by these molecules to realise their potential for use in vaccines and therapies for autoimmune disease in humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14965302     DOI: 10.2174/1568026043451230

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  8 in total

1.  Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.

Authors:  Audrey Glynn; Chad J Roy; Bradford S Powell; Jeffrey J Adamovicz; Lucy C Freytag; John D Clements
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

2.  Stable dry powder formulation for nasal delivery of anthrax vaccine.

Authors:  Sheena H Wang; Shaun M Kirwan; Soman N Abraham; Herman F Staats; Anthony J Hickey
Journal:  J Pharm Sci       Date:  2011-09-08       Impact factor: 3.534

3.  Protective immunity against Naegleria fowleri infection on mice immunized with the rNfa1 protein using mucosal adjuvants.

Authors:  Jinyoung Lee; Jong-Kyun Yoo; Hae-Jin Sohn; Hee-kyoung Kang; Daesik Kim; Ho-Joon Shin; Jong-Hyun Kim
Journal:  Parasitol Res       Date:  2015-01-22       Impact factor: 2.289

4.  A case of milk-protein-induced enterocolitis associated with enterotoxigenic E. coli and MRSA infections.

Authors:  Nemuko Omata; Yusei Ohshima; Akiko Yamada; Motoko Yasutomi; Shuko Tokuriki; Mitsufumi Mayumi
Journal:  Eur J Pediatr       Date:  2007-06-21       Impact factor: 3.183

5.  Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside-binding activities.

Authors:  Hesham F Nawar; Sergio Arce; Michael W Russell; Terry D Connell
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

6.  Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants.

Authors:  Hesham F Nawar; Sergio Arce; Michael W Russell; Terry D Connell
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

7.  Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.

Authors:  Rui Tada; Shoko Muto; Tomoko Iwata; Akira Hidaka; Hiroshi Kiyono; Jun Kunisawa; Yukihiko Aramaki
Journal:  BMC Res Notes       Date:  2017-01-26

8.  Intranasal Immunization with DOTAP Cationic Liposomes Combined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and Systemic Immune Responses in Mice.

Authors:  Rui Tada; Akira Hidaka; Naoko Iwase; Saeko Takahashi; Yuki Yamakita; Tomoko Iwata; Shoko Muto; Emi Sato; Noriko Takayama; Emi Honjo; Hiroshi Kiyono; Jun Kunisawa; Yukihiko Aramaki
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.